NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 81 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q1 2015. The put-call ratio across all filers is 67.56 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $18,000 | 0.0% | 50,201 | +0.6% | 0.00% | – |
| Q4 2017 | $18,000 | -21.7% | 49,895 | -11.1% | 0.00% | – |
| Q3 2017 | $23,000 | -14.8% | 56,126 | +5.2% | 0.00% | – |
| Q2 2017 | $27,000 | -12.9% | 53,345 | 0.0% | 0.00% | – |
| Q1 2017 | $31,000 | 0.0% | 53,345 | +6.8% | 0.00% | – |
| Q4 2016 | $31,000 | -32.6% | 49,927 | 0.0% | 0.00% | – |
| Q3 2016 | $46,000 | +130.0% | 49,927 | +235.1% | 0.00% | – |
| Q4 2015 | $20,000 | -35.5% | 14,901 | +9.1% | 0.00% | – |
| Q3 2015 | $31,000 | 0.0% | 13,662 | -29.6% | 0.00% | – |
| Q2 2015 | $31,000 | +10.7% | 19,401 | +8.9% | 0.00% | – |
| Q1 2015 | $28,000 | -12.5% | 17,808 | +4.6% | 0.00% | – |
| Q4 2014 | $32,000 | +60.0% | 17,028 | +9.7% | 0.00% | – |
| Q3 2014 | $20,000 | -16.7% | 15,518 | -5.7% | 0.00% | – |
| Q2 2014 | $24,000 | 0.0% | 16,454 | +25.7% | 0.00% | – |
| Q1 2014 | $24,000 | -20.0% | 13,094 | -9.9% | 0.00% | – |
| Q4 2013 | $30,000 | 0.0% | 14,528 | +30.0% | 0.00% | – |
| Q2 2013 | $30,000 | – | 11,172 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 15,575,946 | $14,711,000 | 89.51% |
| Financial Advisory Group | 10,000 | $356,000 | 0.17% |
| COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,704,067 | $6,332,000 | 0.05% |
| LifePlan Financial Group, Inc | 28,810 | $27,000 | 0.02% |
| Greenwich Wealth Management LLC | 65,066 | $61,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 649,880 | $614,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $17,000 | 0.01% |
| SII INVESTMENTS INC/WI | 90,315 | $86,000 | 0.01% |
| Stratos Wealth Partners, LTD. | 42,535 | $40,000 | 0.00% |
| SVB WEALTH LLC | 46,262 | $44,000 | 0.00% |